番茄社区

Pfizer dropped development of lotiglipron, its investigational GLP-1 receptor agonist for obesity, ; could other agents in the drug class carry similar risks? (Fierce Biotech)

Amazon Pharmacy plans to automatically apply manufacturers' to ease consumers' price concerns. (USA Today)

But many with diabetes are still struggling to . (Bloomberg Law)

Compared with men, carried a higher risk for developing cardiovascular disease, but these risk differences were mostly explained by obesity status and antihypertensive or statin use. (The Lancet Regional Health Europe)

A national survey of ob/gyn residency program directors found 93% strongly agreed that residents nationwide should have access to that could be utilized in their programs, but only 31% said they had a menopause curriculum in their program. (Menopause)

A push to get obesity services, including drugs, is underway in Congress. (The Hill)

Novo Nordisk Inversago Pharma, which has a cannabinoid receptor blocker in phase II development as a potential weight loss agent. (Reuters)

The first oral liquid diabetes medication was , Boehringer Ingelheim announced.

Novo Nordisk's CEO said limits on (Wegovy) will continue into next year as the company tries to keep up with demand. (Reuters)

Comment